ALDX · Aldeyra Therapeutics, Inc.
$1.75
+0.05 (+2.94%)
At close · Jul 21
Market Cap
$105.56M
Shares
60.32M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$33.85M
+39.4%
FY2025
Diluted EPS
-$0.56
+40.4%
FY2025
Operating Cash Flow
-$33.35M
+22.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $20.65M | $25.66M | $48.22M | $29.46M | $47.31M | $44.94M | $24.68M | $44.35M | $29.82M | $16.3M | $13.18M | $7.57M | $3.71M | $1.54M | — | — | — | — | — | — | — | — | |
| $7.74M | $9.6M | $11.89M | $13.34M | $15.37M | $11.28M | $9.99M | $12.15M | $9.88M | $6.19M | $5.52M | $4.41M | $3.56M | $2.13M | — | — | — | — | — | — | — | — | |
| -$28.38M | -$35.27M | -$60.12M | -$42.79M | -$62.68M | -$56.22M | -$36.42M | -$63.07M | -$39.7M | -$22.49M | -$18.7M | -$11.99M | -$7.27M | -$3.68M | — | — | — | — | — | — | — | — | |
| $1.89M | $1.91M | $1.93M | $2.07M | $1.69M | $1.74M | $1.9M | $603.85K | $146.79K | $113.45K | $105.51K | $112.31K | $244.17K | $159.32K | — | — | — | — | — | — | — | — | |
| $2.91M | $3.32M | $6.19M | $7.32M | $2.35M | $185.36K | $292.22K | $1.54M | $952.7K | $261.25K | $102.04K | $11.13K | $3 | $31 | — | — | — | — | — | — | — | — | |
| $1.01M | $1.42M | $4.27M | $5.25M | $655.35K | -$1.56M | -$1.61M | $937.5K | $805.91K | $147.8K | -$3472 | -$101.18K | $2.08M | $16.74M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | -$57.78M | -$38.03M | -$62.14M | -$38.89M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $1000 | $0 | $0 | $0 | -$479.27K | -$1.31M | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| -$27.37M | -$33.85M | -$55.85M | -$37.54M | -$62.02M | -$57.78M | -$37.55M | -$60.83M | -$38.89M | -$22.34M | -$18.7M | -$12.09M | -$5.19M | $13.06M | -$23.07M | -$2.38M | -$3.59M | -$4.98M | -$2.22M | -$523.03K | -$939.03K | -$386.45K | |
| -$14.92M | — | — | — | — | — | — | — | — | — | — | -$12.09M | -$9.57M | $1.11M | — | — | — | — | — | — | — | — | |
| -$27.37M | -$33.88M | -$55.81M | -$37.44M | -$62.13M | -$57.78M | -$37.56M | -$60.81M | -$38.88M | -$22.36M | -$18.69M | -$12.1M | -$5.19M | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | — | — | — | — | — | -$1.40 | -$2.51 | $3.49 | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | — | — | — | — | — | -$1.40 | -$3.09 | -$17.61 | — | — | — | — | — | — | — | — |
| shares | — | 60.06M | 59.48M | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.82M | 318.43K | — | — | — | — | — | — | — | — |
| shares | — | 60.06M | 59.48M | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.85M | 855.51K | — | — | — | — | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.56×
P/E (TTM)
—
Biotechnology median 7.21×
Key facts
CIK
1341235
CUSIP
01438T106
13F (30d)
12 filings
12 filers
Visit website
Investor relations